



Introducing the

## Avastin Support Line

Easy 24-hour access to treatment support and information

### Get Connected to Answers Anytime

The Avastin Support Line is available whenever you or a loved one needs information or support. Simply call 877-4AVASTIN (877-428-2784) to get timely expert advice and answers to your questions about treatment with Avastin.

### Professional Experts Are Ready to Help

Registered oncology nurses are available at any point during your treatment with Avastin to help you with questions or concerns, such as:

- Learning about treatment with Avastin
- Staying informed through ongoing support by phone or e-mail
- Finding out more about reimbursement for Avastin therapy
- Learning about other resources that can help you with your fight

**Call anytime for expert answers and support**

**877-4AVASTIN** (877-428-2784)

It's important to remember that the Avastin Support Line is not a substitute for your health care provider. Always discuss with your health care team any questions you may have about cancer treatment.

#### Who is Avastin for?

Avastin, in combination with carboplatin and paclitaxel (chemotherapy), is approved by the FDA for first-line treatment of people with unresectable, locally advanced, recurrent, or metastatic non-squamous, non-small cell lung cancer.

Avastin, in combination with intravenous 5-fluorouracil-based chemotherapy, is approved by the FDA for first- or second-line treatment of people with metastatic cancer of the colon or rectum.

Avastin, in combination with interferon alfa, is approved by the FDA for the treatment of metastatic kidney cancer.

Please see reverse side for Serious Side Effects With Avastin, and see the accompanying full Product Information for **Boxed WARNINGS** and additional important safety information.

[www.Avastin.com](http://www.Avastin.com)

**AVASTIN**<sup>®</sup>  
bevacizumab

## Serious Side Effects With Avastin

**Gastrointestinal (GI) perforation:** GI perforation, which is the development of a hole in the stomach, small intestine, or large intestine, may occur. In clinical trials, this event occurred in more people (0.3% to 2.4%) who received Avastin than in the comparison group, and in some cases resulted in fatality. Avastin therapy should be permanently stopped if GI perforation occurs.

**Surgery and wound healing problems:** Slow or incomplete wound healing (for example, when a surgical incision has trouble healing or staying closed) may occur. Surgery and wound healing problems occurred more often in people who received Avastin than in the comparison group, and in some cases resulted in fatality. Avastin therapy should not be started for at least 28 days after surgery and until the surgical wound is fully healed. The length of time between stopping Avastin and having voluntary surgery without the risk of having surgery and wound healing problems has not been determined. Treatment with Avastin should be stopped at least 28 days before voluntary surgery and in people with surgery and wound healing problems that require medical treatment.

**Severe bleeding:** Serious bleeding, including coughing up blood, bleeding in the stomach, vomiting of blood, bleeding in the brain, nosebleeds, and vaginal bleeding may occur. These events occurred up to 5 times more often in people who received Avastin. Across cancer types, 1.2% to 4.6% of people who received Avastin experienced severe to fatal bleeding. People who have recently coughed up blood (greater than or equal to a half teaspoon of red blood) or have serious bleeding should not receive Avastin. Treatment with Avastin should be permanently stopped if serious bleeding occurs (ie, requiring medical attention).

**Additional serious side effects:** In clinical trials for different cancer types, there were additional serious, and sometimes fatal, side effects that occurred in more people who received Avastin than in those in the comparison group. The formation of an abnormal passage from parts of the body to another part was seen in 0.3% or less of people. Severe to life-threatening stroke or heart problems were seen in 2.4% of people. Too much protein in the urine, which led to kidney problems, was seen in less than 1% of people. Additional serious side effects that occurred in more people who received Avastin than those in the comparison group included severe to life-threatening high blood pressure, which was seen in 5% to 18% of people, and nervous system and vision disturbances (reversible posterior leukoencephalopathy syndrome), which was seen in less than 0.1% of people. Infusion reactions with the first dose of Avastin were uncommon and occurred in less than 3% of people, and severe reactions occurred in 0.2% of people.

**Common side effects:** Common side effects that occurred in more than 10% of people who received Avastin for different cancer types, and at least twice the rate of the comparison group, were nosebleeds, headache, high blood pressure, inflammation of the nose, too much protein in the urine, taste change, dry skin, rectal bleeding, tear production disorder, back pain, and inflammation of the skin (exfoliative dermatitis). Across all trials, treatment with Avastin was permanently stopped in 8.4% to 21% of people because of side effects.

Please see the accompanying full Prescribing Information for **Boxed WARNINGS** and additional important safety information.

